The Dyslipidemia drugs in development market research report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dyslipidemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued products.

GlobalData tracks 186 drugs in development for Dyslipidemia by 115 companies/universities/institutes. The top development phase for Dyslipidemia is preclinical with 56 drugs in that stage. The Dyslipidemia pipeline has 167 drugs in development by companies and 19 by universities/ institutes. Some of the companies in the Dyslipidemia pipeline products market are: Addpharma, Kuhnil Pharmaceutical and Chong Kun Dang Pharmaceutical.

The key targets in the Dyslipidemia pipeline products market include 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC, Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.), and Angiopoietin Related Protein 3 (Angiopoietin 5 or Angiopoietin Like Protein 3 or ANG 5 or ANGPTL3).

The key mechanisms of action in the Dyslipidemia pipeline product include 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase (HMG CoA Reductase or Hydroxymethylglutaryl CoA Reductase or HMGCR or EC Inhibitor with 18 drugs in Pre-Registration. The Dyslipidemia pipeline products include five routes of administration with the top ROA being Oral and 14 key molecule types in the Dyslipidemia pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.

Dyslipidemia overview

Dyslipidemia is defined as elevation of the total cholesterol, the “bad” low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the “good” high-density lipoprotein (HDL) cholesterol concentration in the blood. Numerous factors and causes can lead to an abnormality in the levels of lipids in the blood such as genetic predisposition, diet, age and gender, and type 2 diabetes. Common symptoms that may be encountered in relation to dyslipidemia include corneal opacification, corneal arcus, xanthomas, balance impairment, pain in the calf when walking, dizziness, and confusion.

For a complete picture of Dyslipidemia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.